| 1 |
33655823 | Natural Sourced Inhibitors of EGFR, PDGFR, FGFR and VEGFRMediated Signaling Pathways as Potential Anticancer Agents. | 2022 |
1 |
| 2 |
34111559 | Phosphorylation of TRIP13 at Y56 induces radiation resistance but sensitizes head and neck cancer to cetuximab. | 2022 Jan 5 |
1 |
| 3 |
34742684 | A review on epidermal growth factor receptor's role in breast and non-small cell lung cancer. | 2022 Jan 5 |
2 |
| 4 |
35197444 | Numb-PRRL promotes TGF-β1- and EGF-induced epithelial-to-mesenchymal transition in pancreatic cancer. | 2022 Feb 23 |
2 |
| 5 |
31657688 | In Silico Identification of Novel Flavonoids Targeting Epidermal Growth Factor Receptor. | 2021 |
3 |
| 6 |
31957251 | Cost-effectiveness of icotinib versus whole-brain irradiation with or without chemotherapy in EGFR-mutant NSCLC patients with brain metastases. | 2021 Apr |
1 |
| 7 |
32964398 | The G Protein-Coupled Receptor PAC1 Regulates Transactivation of the Receptor Tyrosine Kinase HER3. | 2021 Aug |
1 |
| 8 |
33319463 | Piptides: New, Easily Accessible Chemotypes For Interactions With Biomolecules. | 2021 Mar 15 |
1 |
| 9 |
33338921 | Hexameric procyanidins inhibit colorectal cancer cell growth through both redox and non-redox regulation of the epidermal growth factor signaling pathway. | 2021 Jan |
2 |
| 10 |
33529490 | Clinical impact of rebiopsy among patients with epidermal growth factor receptor-mutant lung adenocarcinoma in a real-world clinical setting. | 2021 Mar |
2 |
| 11 |
33786875 | Involvement of the A disintegrin and metalloproteinase 9 in oral cancer cell invasion. | 2021 Jun |
1 |
| 12 |
33883672 | EGFR-dependent tyrosine phosphorylation of integrin β4 is not required for downstream signaling events in cancer cell lines. | 2021 Apr 21 |
2 |
| 13 |
33976119 | EGFR phosphorylates HDAC1 to regulate its expression and anti-apoptotic function. | 2021 May 11 |
2 |
| 14 |
34066157 | Tumor Extrinsic Factors Mediate Primary T-DM1 Resistance in HER2-Positive Breast Cancer Cells. | 2021 May 12 |
2 |
| 15 |
34415295 | An integrated computational pipeline for designing high-affinity nanobodies with expanded genetic codes. | 2021 Nov 5 |
2 |
| 16 |
34725466 | EGFR Regulates the Hippo pathway by promoting the tyrosine phosphorylation of MOB1. | 2021 Nov 1 |
1 |
| 17 |
34917992 | Response to Icotinib Plus Chemotherapy in Pulmonary Atypical Carcinoid Harboring the EGFR L858R Mutation: A Brief Report. | 2021 Dec |
1 |
| 18 |
31562907 | Clathrin switches transforming growth factor-β role to pro-tumorigenic in liver cancer. | 2020 Jan |
2 |
| 19 |
31595681 | FTIR spectra signatures reveal different cellular effects of EGFR inhibitors on nonsmall cell lung cancer cells. | 2020 Mar |
1 |
| 20 |
31601525 | Clinical Features and Progression Pattern of Acquired T790M-positive Compared With T790M-negative EGFR Mutant Non-small-cell Lung Cancer: Catching Tumor and Clinical Heterogeneity Over Time Through Liquid Biopsy. | 2020 Jan |
2 |
| 21 |
31659695 | Comprehensive bioinformatics study reveals targets and molecular mechanism of hesperetin in overcoming breast cancer chemoresistance. | 2020 Nov |
1 |
| 22 |
31672763 | Radiation Responses of 2D and 3D Glioblastoma Cells: A Novel, 3D-specific Radioprotective Role of VEGF/Akt Signaling through Functional Activation of NHEJ. | 2020 Feb |
1 |
| 23 |
31674165 | Morule-like features in pulmonary adenocarcinoma associated with epidermal growth factor receptor mutations: two case reports with targeted next-generation sequencing analysis. | 2020 Jan |
2 |
| 24 |
31691525 | Circulating plasma lncRNAs as novel markers of EGFR mutation status and monitors of epidermal growth factor receptor-tyrosine kinase inhibitor therapy. | 2020 Jan |
5 |
| 25 |
31698509 | Dual inhibition of EGFR and MET by Echinatin retards cell growth and induces apoptosis of lung cancer cells sensitive or resistant to gefitinib. | 2020 Feb |
1 |
| 26 |
31710890 | Impact of coexisting gene mutations in EGFR-mutated non-small cell lung cancer before treatment on EGFR T790M mutation status after EGFR-TKIs. | 2020 Jan |
3 |
| 27 |
31715539 | Detection of rare and novel EGFR mutations in NSCLC patients: Implications for treatment-decision. | 2020 Jan |
6 |
| 28 |
31735523 | Incidence of T790M in Patients With NSCLC Progressed to Gefitinib, Erlotinib, and Afatinib: A Study on Circulating Cell-free DNA. | 2020 May |
2 |
| 29 |
31736196 | Sensitization of HT29 colorectal cancer cells to vemurafenib in three-dimensional collagen cultures. | 2020 Feb |
1 |
| 30 |
31743131 | Transcriptionally Active HPV and Targetable EGFR Mutations in Sinonasal Inverted Papilloma: An Association Between Low-risk HPV, Condylomatous Morphology, and Cancer Risk? | 2020 Mar |
1 |
| 31 |
31747091 | Molecular genetics of cutaneous squamous cell carcinoma: perspective for treatment strategies. | 2020 May |
1 |
| 32 |
31751804 | Predictive impact of low-frequency pretreatment T790M mutation in patients with EGFR-mutated non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors. | 2020 Jan |
5 |
| 33 |
31755215 | Photobodies: Light-Activatable Single-Domain Antibody Fragments. | 2020 Jan 20 |
1 |
| 34 |
31758670 | Activation of insulin-like growth factor-1 receptor confers acquired resistance to osimertinib in non-small cell lung cancer with EGFR T790M mutation. | 2020 Jan |
1 |
| 35 |
31761448 | Evidence of NTRK1 Fusion as Resistance Mechanism to EGFR TKI in EGFR+ NSCLC: Results From a Large-Scale Survey of NTRK1 Fusions in Chinese Patients With Lung Cancer. | 2020 May |
3 |
| 36 |
31777985 | mPRα mediates P4/Org OD02-0 to improve the sensitivity of lung adenocarcinoma to EGFR-TKIs via the EGFR-SRC-ERK1/2 pathway. | 2020 Feb |
4 |
| 37 |
31778239 | Elevation in serum uric acid levels predicts favourable response to erlotinib treatment in patients with metastatic non-small-cell lung cancer. | 2020 Apr |
2 |
| 38 |
31782583 | Phase I study of vorinostat with gefitinib in BIM deletion polymorphism/epidermal growth factor receptor mutation double-positive lung cancer. | 2020 Feb |
2 |
| 39 |
31785991 | Combination of EGFR-TKIs and chemotherapy in advanced EGFR mutated NSCLC: Review of the literature and future perspectives. | 2020 Feb |
1 |
| 40 |
31786475 | Uncommon EGFR mutations associate with lower incidence of T790M mutation after EGFR-TKI treatment in patients with advanced NSCLC. | 2020 Jan |
1 |
| 41 |
31789388 | Clinical importance of long non‑coding RNA LINC00460 expression in EGFR‑mutant lung adenocarcinoma. | 2020 Jan |
3 |
| 42 |
31805304 | 20(S)-Protopanaxadiol blocks cell cycle progression by targeting epidermal growth factor receptor. | 2020 Jan |
1 |
| 43 |
31809241 | Osimertinib in Patients With Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer and Leptomeningeal Metastases: The BLOOM Study. | 2020 Feb 20 |
1 |
| 44 |
31830556 | Proliferative signaling by ERBB proteins and RAF/MEK/ERK effectors in polycystic kidney disease. | 2020 Mar |
3 |
| 45 |
31839416 | Next-generation sequencing based mutation profiling reveals heterogeneity of clinical response and resistance to osimertinib. | 2020 Mar |
1 |
| 46 |
31841994 | Long Noncoding RNA LINC01116 Contributes to Gefitinib Resistance in Non-small Cell Lung Cancer through Regulating IFI44. | 2020 Mar 6 |
2 |
| 47 |
31846863 | Prognostic factors of EGFR-mutated metastatic adenocarcinoma of lung. | 2020 Feb |
2 |
| 48 |
31859066 | Clinicopathologic Characteristics, Treatment Outcomes, and Acquired Resistance Patterns of Atypical EGFR Mutations and HER2 Alterations in Stage IV Non-Small-Cell Lung Cancer. | 2020 May |
1 |
| 49 |
31865062 | Naquotinib exerts antitumor activity in activated B-cell-like diffuse large B-cell lymphoma. | 2020 Jan |
1 |
| 50 |
31869496 | Annexin A6 improves anti-migratory and anti-invasive properties of tyrosine kinase inhibitors in EGFR overexpressing human squamous epithelial cells. | 2020 Jul |
2 |